Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as chief medical officer.
SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s and Parkinson’s Diseases. Presentation and discussion session details are included below.
SAN CARLOS, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the publication of a peer-reviewed article in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. The publication titled, “Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia,” describes Alkahest’s Phase 2 clinical trial investigating GRF6019 as a potential treatment for patients with Alzheimer’s disease (AD) and is available online here.
BARCELONA, Spain, and SAN CARLOS, Calif., Sept. 7, 2020 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional financing will be required.
- Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021
SAN CARLOS, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today provided a corporate update.
SAN CARLOS, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin (B2M) from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease (ESRD).
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease. The trial, AKST4290-211 (TEAL), is funded in part by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and will evaluate the effect of AKST4290 on motor function and activities of daily living in patients with Parkinson’s disease.
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has treated the first patient in trial AKST4290-206 (STEEL) studying the effect of AKST4290 on choroidal blood flow (ChBF) in patients with neovascular age-related macular degeneration (AMD).